Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects

Spiegelstein, O.; Stevens, J.; Gerven, J. van; Nathan, P.J.; Maynard, J.P.; Mayleben, D.W.; ... ; Yang, R.H. (2016)

Article / Letter to editor

• Pharmacokinetics and drug metabolism
• pharmacodynamics (PDY)
• population pharmacokinetics
• central nervous system (CNS)
• clinical trials (CTR)
• histamine-3 receptor antagonist

• All authors: Spiegelstein, O.; Stevens, J.; Gerven, J. van; Nathan, P.J.; Maynard, J.P.; Mayleben, D.W.; Hellriegel, E.; Yang, R.H.
• Date: 2016-10-31
• Journal: Journal of Psychopharmacology
• Volume: 30
• Issue: 10
• Pages: 983 - 993
• DOI: doi:10.1177/0269881116645301